Delivery Order SPE2DB22D1103-SPE2DB25FH2M8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $19,408.76. This firm fixed-price delivery order, with an ultimate completion date of September 4, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, on September 15, 2025, for the supply of Gemtesa 75 mg tablets in a quantity of 90 units. The contract is a firm fixed price delivery order with a ceiling value of $5,677.67 and an ultimate completion date of September 16, 2025. This award was competitively awarded with no set-aside designation and represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $7,772.26 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). The contract represents a firm fixed price, non-set-aside award with an ultimate completion date of September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $8,782.31. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order valued at $7,531.09 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on September 4, 2025, with completion expected by September 5, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $92,969.92 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH2M8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gemtesa 75 mg tablets (90-count) valued at $1,988.78. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026 that supports military healthcare programs globally. AmerisourceBergen Drug Corp, one of the nation's leading pharmaceutical distributors, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering a broad spectrum of pharmaceutical products, including specialty medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This specific delivery order for Gemtesa, a medication used in urology, exemplifies the company's role in fulfilling ongoing pharmaceutical supply needs for the Defense Health Agency and other federal healthcare customers through the DLA's flexible contract vehicle structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/17/25 |